Item 1.01. Entry into a Material Definitive Agreement.
On
Pursuant to an Engagement Letter (the "Engagement Letter") with
Also pursuant to the Engagement Letter, the Company, in connection with the
Offering, agreed to grant the Placement Agent or its designees warrants to
purchase an aggregate of up to of 165,000 shares of its common stock (which
represents 7.5% of the Shares sold to investors in the offering) at an exercise
price equal to 125% of the public offering price of the Shares in the offering,
or
The Engagement Letter, form of Warrant and the Securities Purchase Agreement are filed as Exhibits 1.1, 4.1 and 10.1, respectively, and are incorporated into this Current Report on Form 8-K by reference. The foregoing description of such documents is qualified in its entirety by reference to the full text thereof. The press release announcing the Offering is attached hereto as Exhibit 99.1, and is incorporated herein by reference.
The Company currently intends to use the net proceeds from the offering for working capital purposes.
Shares sold under the Agreement will be offered and sold pursuant to the
Company's Registration Statement on Form S-3, which was initially filed on
The opinion of the Company's counsel regarding the validity of the Shares is filed as Exhibit 5.1 to this Current Report on Form 8-K. This opinion is also filed with reference to, and is hereby incorporated by reference into, the Registration Statement.
Item 3.02. Unregistered Sales of
The disclosure in Item 1.01 is incorporated herein by reference thereto. Neither
the warrants issued to the investors or the Placement Agent nor the shares
issuable pursuant to these warrants were registered under the Securities Act of
1933, as amended (the "Securities Act") at the time of sale, and therefore may
not be offered or sold in
Item 9.01. Financial Statements and Exhibits.
(d)Exhibits. Exhibit Number Description Engagement Letter (incorporated by reference to Form 8-K filed January 1.1 12, 2021) 4.1 Form of Warrant 5.1 Opinion ofMaslon LLP Form of Securities Purchase Agreement, datedJanuary 19, 2021 , by and 10.1 betweenPredictive Oncology Inc. and certain Purchasers 23.1 Consent ofMaslon LLP (contained in Exhibit 5.1). 99.1 Press Release
--------------------------------------------------------------------------------
© Edgar Online, source